Ratio Announces Expansion of Manufacturing Agreement with PharmaLogic
Intermountain Health & PharmaLogic Partner to Develop Novel Radiopharmaceuticals
ARTBIO and PharmaLogic Announce Agreement for Candidate AB001
Meilleur Technologies Inc. Announces Execution of Manufacturing Agreement with PharmaLogic for Production of the Next-Generation Amyloid PET Imaging Biomarker, NAV4694
BOSTON, July 11, 2023 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company that employs a suite of innovative technologies to develop best-in-class radiopharmaceuticals for the monitoring and treatment of cancers today announced, in partnership with Lantheus, a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions that enable clinicians to Find, Fight and Follow disease, and in collaboration with PharmaLogic, a world-class contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, that it has initiated dosing in a Phase I study evaluating the pharmacokinetics, biodistribution and radiation dosimetry of a novel fibroblast activation protein-alpha (FAP)-targeted radiopharmaceutical, Copper-64[Cu-64]-labeled RTX-1363S, for PET imaging in adult healthy volunteers.
PITTSBURGH and BOCA RATON, Fla., June 21, 2023 /PRNewswire/ -- As part of its goal of transforming care for its patients through translational research, UPMC today announced a collaboration with PharmaLogic Holdings Corp. to facilitate the development of novel radiopharmaceuticals for the diagnosis and treatment of cancer and other diseases. The partners will jointly construct a world-class radiopharmaceutical research, production and distribution facility in Pittsburgh, expected to be one of the largest such centers in the United States.
BASEL, Switzerland & BOCA RATON, Fla.--(BUSINESS WIRE)--NUCLIDIUM and PharmaLogic Holdings today announced that they have entered into a strategic collaboration agreement for the production and clinical supply of 61Cu in the United States to accelerate the development of NUCLIDIUM’s theranostic pipeline. By combining copper radiometals with highly specific cancer-targeting molecules, NUCLIDIUM’s theranostic approach aims to offer innovative diagnostic and therapeutic treatments for patients suffering from a range of solid tumours. The partnership with PharmaLogic will provide NUCLIDIUM with a sustainable supply of 61Cu in the United States both for its planned clinical trials as well as future commercialized products. NUCLIDIUM has developed a proprietary production process for high-quality 61Cu, a novel diagnostic radioisotope that offers unique properties for safe, economical, and highly efficient diagnostics to improve cancer-staging and subsequent treatment decisions.
PharmaLogic Holdings Corp., a contract development and manufacturing organization (CDMO) and radiopharmaceutical manufacturer, entered into a master services agreement with Viewpoint Molecular Targeting, Inc., a wholly owned subsidiary of Perspective Therapeutics, Inc., for the development and production of theranostic candidates VMT-01 and VMT-?-NET.